Interview: Dong-A’s Journey To Becoming An Original Drug Developer
Executive Summary
Dong-A ST’s Head of Research Taeyoung Yoon talks to Scrip about the leading South Korean pharma’s ambitions to become a developer of original drugs, its innovative drug R&D strategy, and other major achievements as it reshapes its business.
You may also be interested in...
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.